𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Combined effects of cabergoline and L-dopa on parkinsonism in MPTP-treated cynomolgus monkeys

✍ Scribed by N. Arai; M. Isaji; M. Kojima; E. Mizuta; S. Kuno

Publisher
Springer
Year
1996
Tongue
English
Weight
524 KB
Volume
103
Category
Article
ISSN
1435-1463

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

6-[18F]fluoro-L-DOPA PET studies of the
6-[18F]fluoro-L-DOPA PET studies of the turnover of dopamine in MPTP-induced parkinsonism in monkeys
✍ Doris J. Doudet; Grace L.Y. Chan; James E. Holden; Edith G. Mcgeer; Thomas A. Ai πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 83 KB πŸ‘ 2 views

This report describes a method to assess, in vivo, the turnover of dopamine (DA) and describes its application to the evaluation of DA function in normal monkeys and monkeys with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced lesions of the DA nigro-striatal pathway. Using positron emis

Effect of LY 171555 and CY 208-243 on tr
Effect of LY 171555 and CY 208-243 on tremor suppression in the MPTP monkey model of parkinsonism
✍ Baltazar Gomez-Mancilla; RenΓ© Boucher; Dr. Paul J. BΓ©dard πŸ“‚ Article πŸ“… 1992 πŸ› John Wiley and Sons 🌐 English βš– 493 KB

## Abstract The antitremor effect of the D~2~ agonist LY 171555 and of the D~1~ agonist CY 208‐243 alone and in combination was tested in a monkey previously rendered parkinsonian by MPTP and displaying exceptionally a rest termor in the limbs. The D~2~ agonist suppressed rest tremor in a dose‐depe

The effects of cisapride on plasma L-dop
The effects of cisapride on plasma L-dopa levels and clinical response in Parkinson's disease
✍ Walter Diaz Neira; Vicenta Sanchez; Maria Angeles Mena; Dr. Justo Garcia de Yebe πŸ“‚ Article πŸ“… 1995 πŸ› John Wiley and Sons 🌐 English βš– 428 KB πŸ‘ 1 views

Cisapride (CIS) is a prokinetic agent that increases gastrointestinal motility in normal individuals and improves constipation in Parkinson's disease (PD). We studied the effects of CIS on the clinical response and the peripheral pharmacokinetics of orally administered L-dopa given to patients with